7-endo-methyl-3-one-bicyclo<3.3.1>nonane | 35357-02-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-endo-methyl-3-one-bicyclo<3.3.1>nonane
• 英文别名: 7-exo-methyl-3-one-bicyclo<3.3.1>nonane；3-Methyl-bicyclo<3.3.1>nonan-7-on；7-endo-methyl-3-one-bicyclo[3.3.1]nonane；7-exo-methyl-3-one-bicyclo[3.3.1]nonane；3-Methyl-bicyclo[3.3.1]nonan-7-on；7-Methylbicyclo[3.3.1]nonan-3-one
• CAS: 35357-02-9
• 化学式: C₁₀H₁₆O
• mdl: MFCD00499234
• 分子量: 152.236
• InChiKey: MMLOOGBEEZQKPO-UHFFFAOYSA-N

物化性质

• 沸点：
  229.8±8.0 °C(Predicted)
• 密度：
  0.968±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  甲基碘化镁 、 7-endo-methyl-3-one-bicyclo<3.3.1>nonane 以 乙醚 为溶剂， 生成 exo-3,exo-7-Dimethylbicyclo<3.3.1.>nonan-2-en
  参考文献：
  名称：

  Stepanov,F.N. et al., Journal of Organic Chemistry USSR (English Translation), 1971, vol. 7, # 12, p. 2615 - 2617

  摘要：

  DOI：
• 作为产物：
  描述：

  7-亚甲基双环[3.3.1]壬-3-酮 在 platinum(IV) oxide 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 7-endo-methyl-3-one-bicyclo<3.3.1>nonane
  参考文献：
  名称：

  Stepanov,F.N. et al., Journal of Organic Chemistry USSR (English Translation), 1971, vol. 7, # 12, p. 2615 - 2617

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF<br/>[FR] COMPOSÉS PIPÉRIDINE À LIAISON ET SUBSTITUÉS PAR UNE QUINOXALINE, ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2010010458A1

  公开（公告）日：2010-01-28

  The invention relates to Substituted-Quinoxaline-Type Bridged-Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline- Type Bridged-Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

  这项发明涉及取代喹喔啉型桥式哌啶化合物，包括有效量的取代喹喔啉型桥式哌啶化合物的组合物，以及治疗或预防疼痛等疾病的方法，包括向需要治疗的动物施用有效量的取代喹喔啉型桥式哌啶化合物。
• Chemo-Selectivity of Group-VIII Metal Catalysts in Hydrogenation of Nonconjugated Enones
  作者：Jun-ichi Ishiyama、Satoshi Maeda、Kazuhiro Takahashi、Yasuhisa Senda、Shin Imaizumi

  DOI：10.1246/bcsj.60.1721

  日期：1987.5

  of group-VIII metal catalysts has been examined in the hydrogenation of nonconjugated enones at ambient temperature under an atmospheric pressure of hydrogen. A cobalt catalyst gave high yields of unsaturated alcohols from trialkylated olefinic ketones. Osmium showed the highest selectivity among platinum metal catalysts for the reduction of the carbonyl bond in the hydrogenation of trialkylated olefinic

  VIII族金属催化剂的化学选择性已在常温氢气压力下非共轭烯酮的氢化中得到检验。钴催化剂从三烷基化烯烃酮中得到高收率的不饱和醇。在铂金属催化剂中，锇在三烷基化烯烃酮的加氢反应中对羰基键的还原显示出最高的选择性。无论催化剂如何，单烷基化和二烷基化烯烃酮的氢化通常以烯烃官能团的优先饱和进行。4-亚甲基-和4-亚乙基环己酮的氢化伴随着在乙醇溶剂中在钌、铑和钯黑催化剂上形成二乙缩醛。在其他烯酮的氢化和其他催化剂上未检测到缩醛。此外，还研究了镍和钴催化剂对无环烯酮加氢的化学选择性。
• OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：Shionogi & Co., Ltd.

  公开号：US20140187544A1

  公开（公告）日：2014-07-03

  The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 20 , R 21 , Q, Y 1 , Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

  本公开涉及氧肟取代的喹喔啉型哌啶化合物，例如公式（I）中的化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义；包含有效量氧肟取代的喹喔啉型哌啶化合物的组合物，以及治疗或预防疾病的方法，例如疼痛，包括向需要治疗的动物施用有效量的氧肟取代的喹喔啉型哌啶化合物。
• OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS
  申请人：Purdue Pharma L.P.

  公开号：US20150238485A1

  公开（公告）日：2015-08-27

  The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 20 , R 21 , Q, Y 1 , Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

  本公开涉及肟取代的喹噁啉型哌啶化合物，例如式（I）中的化合物及其药学上可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义；包含有效量肟取代的喹噁啉型哌啶化合物的组合物，以及治疗或预防疾病（如疼痛）的方法，包括向需要治疗的动物中有效量的肟取代的喹噁啉型哌啶化合物。
• QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：TADESSE Dawit

  公开号：US20160002203A1

  公开（公告）日：2016-01-07

  The present disclosure relates to Quinazolin-4(3H)-one-Type Piperidine Compounds, such as those of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , Q, Y 1 , Z, A, B, E, and a are as defined herein; compositions comprising an effective amount of a Quinazolin-4(3H)-one-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Quinazolin-4(3H)-one-Type Piperidine Compound.

  本公开涉及喹唑啉-4(3H)-酮型哌啶化合物，例如公式（I）中的化合物及其药学上可接受的盐和溶剂化物，其中R1、R2、R3、Q、Y1、Z、A、B、E和a的定义如本文所述；包含有效量喹唑啉-4(3H)-酮型哌啶化合物的组合物；以及通过向需要治疗或预防疾病，例如疼痛的动物施用有效量喹唑啉-4(3H)-酮型哌啶化合物的方法。